B | Exxon Mobil is buying Pioneer Natural Resources in an all-stock deal valued at $59.5 billion, its largest buyout since acquiring Mobil two decades ago, creating a colossal fracking operator in West Texas. Including debt, Exxon is committing about $64.5 billion to the acquisition, leaving no doubt of the Texas energy company's commitment to fossil fuels as energy prices surge. Pioneer shareholders will receive 2.32 shares of Exxon for each Pioneer share they own.“I think fossil fuels, as the world looks to transition and find lower sources of affordable energy with lower emissions, fossil fuels oil and gas are going to continue to play a role over time,” Exxon Mobil CEO Darren Woods said during an interview with CNBC. “ That may diminish with time. The rate of that is, I think, not very clear at this stage. But it will be around for a long time.” Woods explained that Exxon and Pioneer will be able to use their combined capabilities to drive down emissions and produce lower carbon intensity oil and gas. Exxon purchased XTO Energy in 2009 for approximately $36 billion. In the late 1990s, the merger between Exxon and Mobil was valued around $80 billion.The deal with Pioneer Natural vastly expands Exxon's presence in the Permian basin, a massive oilfield that straddles the border between Texas and New Mexico. Drilling the Permian accounted for 18% of all U.S. natural gas production last year, according to the U.S. Energy Information Administration.Pioneer's more than 850,000 net acres in the Midland Basin will be combined with Exxon’s 570,000 net acres in the Delaware and Midland Basin, nearly contiguous fields that will allow the combined company to trim costs. That is a big driver of the deal. Natural gas rigs in operation have declined over 26% in the U.S. since the start of the year, according to government data, largely due to the rising costs for drilling materials and labor over the past two years. “Their tier-one acreage is highly contiguous, allowing for greater opportunities to deploy our technologies, delivering operating and capital efficiency as well as significantly increasing production,” Woods said of Pioneer in a prepared statement. The company will have an estimated 16 billion barrels of oil equivalent in the Permian.Once the deal closes, Exxon Permian production volume will more than double to 1.3 million barrels of oil equivalent per day, based on 2023 volumes. It's expected to climb to about 2 million barrels of oil equivalent per day in 2027. “The combination of ExxonMobil and Pioneer creates a diversified energy company with the largest footprint of high-return wells in the Permian Basin,” Pioneer CEO Scott Sheffield said in a prepared statement. Citi's Alastair Syme wrote that the transaction could provide multiple benefits to Exxon. “Across the industry, the logic of consolidation in the highly fragmented Permian shale remains compelling with significant gains to be achieved from economies of scale by minimizing facilities spend, optimizing drilling and reducing" general spending, Syme wrote. Exxon is flush with cash. The company posted unprecedented profits last year of $55.7 billion, breezing past its previous record of $45.22 billion in 2008 when oil prices hit record highs.Exxon Mobil Corp. has been using some of that cash on acquisitions. In July the company announced that it was buying pipeline operator Denbury in an all-stock deal valued at $4.9 billion.Pioneer Natural has been making similar maneuvers. In 2020 the company said it was buying Parsley Energy in an all-stock deal valued at approximately $4.5 billion. It then purchased DoublePoint Energy in a cash-and-stock deal worth about $6.4 billion in 2021.The boards of both companies have approved the transaction, which is expected to close in the first half of next year. It still needs approval from Pioneer shareholders. Shares of Exxon fell more than 4% in Wednesday morning trading.。8月17日至23日，共有34款1类创新药首次在中国获批临床试验默示许可。

C | 还有一组更亮眼的数据：今年上半年，中国创新药对外授权共达成81笔合作，交易总额约1100亿美元，已经达到2025年全年总额的80%，再创历史同期新高。　　业内专家表示，这背后更重要的是中国创新药企角色的根本性转变。从过去的“原料供应商”，升级为与跨国药企平等对话、利益共享的“全球合伙人”。　　上半年科创板创新药企业绩亮眼　　创新药因研发难度大、附加值高，被誉为医药产业“皇冠上的明珠”。2026年上半年，科创板创新药企交出了漂亮“成绩单”。

D | 　　诺诚健华报告显示，上半年营收同比增长55.5%，达到11.4亿元，净利润2.4亿元，同比扭亏为盈。泽璟制药也交出上市以来首份盈利半年报，百济神州则交出史上最优半年度成绩单。　　“科创板创新药企业已经开始进入盈利兑现期。”苏商银行特约研究员武泽伟分析，“当前，创新药行业的商业化能力修复，海外权益合作持续落地，有效补充企业的运营现金流。国内审评与支付机制不断优化，缩短新药的上市周期，拓宽产品收入边界。依托完整的产业链红利，国内的生物医药配套体系日趋成熟，研发服务企业持续承接海内外订单，充分分享全球研发投入回暖带来的业务增量。”　　中国创新药对外授权交易额迭创新高　　中国创新药获得全球市场的认可。2025年全年，中国药企的对外授权潜在交易总金额高达1356.55亿美元，是2024年的两倍多，一举登顶全球首位。今年上半年，中国创新药对外授权交易总额约1100亿美元，达到了去年全年总额的八成，再创历史新高。　　国家药监局药品注册管理司副司长蓝恭涛介绍，中国在研新药数量约占全球30%，位列全球第二。中国医药产业创新效率居世界前列。　　蓝恭涛说：“2025年我国批准的11个新靶点、新机制药品中，4个是国产创新药，占比不到一半。今年上半年，我国批准的11个新靶点、新机制药品全都是自主研发的国产创新药。”　　中国药企正从“跟跑者”转变为“合作者”　　中国创新药实现了从“卖产品”到“卖技术”的跨越，中国创新药企业正在以“全球合作伙伴”的身份，与跨国药企联合开发、共享收益。　　武泽伟说：“未来，行业会逐步脱离同质化跟随研发，转向全新靶点与全新机制的源头创新。出海模式也从早期对外授权，过渡到自主完成海外申报与全球商业化运营。产业从产品出海升级为技术平台与研发体系的对外输出，整体国际竞争力稳步增强。”　　国家医保局近日发布《全民医疗保障“十五五”规划》，明确支持创新药纳入医保、推动商保创新药目录，释放强烈利好信号。